Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model  by Mielcarek, Marco et al.
D
G
H
I
a
(
(
a
m
i
r
m
a
[
c
w
c
m
G
f
Biology of Blood and Marrow Transplantation 12:899-904 (2006)
 2006 American Society for Blood and Marrow Transplantation
1083-8791/06/1209-0001$32.00/0
doi:10.1016/j.bbmt.2006.05.005enileukin Diftitox as Prophylaxis against
raft-versus-Host Disease in the Canine
ematopoietic Cell Transplantation Model
Marco Mielcarek,1,2 George E. Georges,1,2 Rainer Storb1,2
1Fred Hutchinson Cancer Research Center, Seattle, Washington; 2University of Washington,
Department of Medicine, Seattle, Washington
Correspondence and reprint requests: Marco Mielcarek, MD, Fred Hutchinson Cancer Research Center, 1100
Fairview Avenue North, D1-100, P.O. Box 19024, Seattle, WA 98109-1024 (e-mail: mmielcar@fhcrc.org).
Received March 30, 2006; accepted May 18, 2006
ABSTRACT
Denileukin diftitox (Ontak) was evaluated in combination with methotrexate (MTX) for preventing acute
graft-versus-host disease (GVHD) in dogs given 9.2 Gy of total body irradiation and DLA-nonidentical
hematopoietic cell grafts. Six dogs were given denileukin diftitox 9 g/kg/day intravenously (IV) on days 2, 4,
5, 7, 8, and 10, in combination with MTX 0.4 mg/kg/day IV on days 1, 3, 6, and 11 after transplantation. Median
survival of the dogs given MTX in combination with denileukin diftitox was 16 days (range, 13-18 days), similar
to that of 35 historical controls given MTX alone (median survival, 20 days). Five of the 6 denileukin
diftitox–treated dogs had clinical and pathological evidence of 3-system GVHD; 1 dog died of canine herpes
virus infection without evidence of GVHD. In conclusion, denileukin diftitox did not prevent, mitigate, or delay
acute GVHD in this stringent and predictive (with respect to outcomes in human patients) hematopoietic cell
transplantation model.
© 2006 American Society for Blood and Marrow Transplantation
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nNTRODUCTION
A main purpose of immunosuppressive therapy
fter allogeneic hematopoietic cell transplantation
HCT) is the prevention of graft-versus-host disease
GVHD), a major cause of mortality and morbidity
fter transplantation. The immunosuppressive regi-
ens most widely in clinical use combine calcineurin
nhibitors with antimetabolites. Using a combination
egimen of cyclosporine (CSP) and a short course of
ethotrexate (MTX) developed in the dog leukocyte
ntigen (DLA)-nonidentical canine transplant model
1,2], for example, incidence and severity of GVHD
ould be lowered substantially [3]. However, even
ith postgrafting CSP and MTX, acute GVHD oc-
urs in 40%-80% of human recipients of HLA-
atched grafts, illustrating the need for more effective
VHD prophylaxis [4,5].
Denileukin diftitox (Ontak) is a recombinantusion protein composed of amino acid sequences por diphtheria toxin fragments A and B followed by
he sequences for human interleukin (IL)-2 [6]. De-
ileukin diftitox preferentially binds to the high-
fﬁnity IL-2R expressed on activated T cells [7]
nd, after internalization of the receptor–ligand
omplex, kills T cells by inhibiting protein synthesis
8]. Denileukin diftitox has been shown to have
ntitumor effects in patients with cutaneous T-cell
ymphoma and non-Hodgkin’s lymphoma whose
alignant cells express IL-2R [9,10]. More recently,
enileukin diftitox has been used to treat steroid-
efractory acute GVHD and showed promising ac-
ivity, with complete response rates of 50%-59%
11,12]. We therefore hypothesized that denileukin
iftitox would be effective in the prevention of acute
VHD. After demonstrating cross-reactivity of de-
ileukin diftitox with canine T-cells in vitro, we
ested our hypothesis in the DLA-nonidentical ca-
ine transplantation model, which has been highly
redictive of outcome in humans [3].
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anine Mixed Lymphocyte Cultures
A total of 105 responder peripheral blood mono-
uclear cells (PBMCs) were cultured with 105 irradi-
ted (24 Gy), allogeneic, DLA-mismatched stimulator
BMCs at 106/mL for 6 days according to established
ethods [13]. Deﬁned concentrations (108-1011.5
olar) of denileukin diftitox (Ontak; Ligand Pharma-
euticals, San Diego, CA) or sera from denileukin
iftitox–treated dogs were added to canine mixed lym-
hocyte cultures (MLCs) at the beginning of the cul-
ure. Cells were labeled with 1 Ci/well of 3H-thy-
idine for the ﬁnal 16 hours of culture, harvested
nto glass ﬁber ﬁlters, and counted for isotope incor-
oration.
ematopoietic Cell Transplantation
The Institutional Animal Care and Use Commit-
ee of the Fred Hutchinson Cancer Research Center
pproved this study. Hematopoietic cell grafts were
arried out using beagle or miniature mongrel–beagle
rossbreeds, and standard care was provided as described
reviously [2,14,15]. Recipients (autologous, n  3; al-
ogeneic, n 6) were age 8.0-73.8 months (median, 12.9
onths) and weighed 8.5-12.9 kg (median, 10.7 kg). The
onors (n  6) were age 6.7-15.4 months (median, 13.1
onths), of different pedigrees for at least 5 generations,
nd chosen on the basis of nonidentity for highly poly-
orphic major histocompatibility complex class I and II
icrosatellite marker polymorphisms and DLA-DRB1
lleles [16,17].
On day 0, donor marrow was harvested and in-
used intravenously (IV) into autologous (n  3) or
llogeneic (n  6) recipients within 4 hours after a
ingle 9.2-Gy dose (7 cGy/min) of total body irradia-
ion (TBI) (Varian Clinac 4; Varian Medical Systems,
alo Alto, CA).
Allogeneic transplant recipients were given MTX
.4 mg/kg IV on days 1, 3, 6, and 11 and denileukin
iftitox 9 g/kg/day IV on days 2, 4, 5, 7, 8, and 10.
utologous marrow transplantation with postgrafting
TX and denileukin diftitox (9 g/kg/day  6 days,
 2; 18 g/kg/day  6 days, n  1) was done to
etermine denileukin diftitox toxicity after myeloab-
ative conditioning in the absence of allogeneic effects.
he median number of nucleated marrow cells in-
used was 5.4  108 cells/kg (range, 3.8-6.9 108
ells/kg). In addition, PBMCs were harvested from
llogeneic donors by leukapheresis (Cobe BCT, Lake-
ood, CO) and infused IV on day 1 (median number,
.2  108 cells/kg; range, 1.8-11.7 108 cells/kg).
Clinical signs of cute GVHD included diarrhea, skin
rythema, and elevated liver enzyme values. Any dog in
oor clinical condition was euthanized, and a complete
ecropsy was performed to allow histopathologic dis-
inction between GVHD and regimen-related toxicities. engraftment was assessed based on sustained hemato-
oietic recovery after the postirradiation nadir, histolog-
cal features of the marrow, and documentation of donor
icrosatellite marker polymorphisms in blood and mar-
ow by polymerase chain reaction [18].
Results from current recipients were compared
ith those of 3 groups of previously published and
oncurrent DLA-nonidentical, unrelated HCT recip-
ents, all of which received 9.2 Gy TBI and HCT, as
id the dogs in the current study [2,18-21]. The dogs
n control group 1 received no postgrafting immuno-
uppression, the dogs in group 2 were given MTX
lone, and the dogs in group 3 received a combination
f MTX and CSP.
ESULTS
enileukin Diftitox Inhibits T-Cell Proliferative
esponsiveness in Canine Allogeneic MLCs
Figure 1 shows the dose-dependent inhibition of
anine allogeneic MLCs by deﬁned concentrations of
enileukin diftitox added at the initiation of culture.
he results demonstrate a complete abrogation of
lloantigen-induced T-cell proliferation in the pres-
nce of 1010 molar concentrations of denileukin
iftitox.
era Obtained from Dogs after IV Injection
f Denileukin Diftitox Exhibit
-Cell–Inhibitory Activity
We then investigated whether dogs given single
V injections of denileukin diftitox achieved serum
oncentrations sufﬁcient to inhibit proliferation of
lloactivated T cells. We found that sera obtained
rom dogs 20 minutes after a single 9-g/kg IV injec-
ion of denileukin diftitox completely inhibited the
igure 1. Inhibition of proliferative responsiveness in canine allo-
eneic MLCs by denileukin diftitox. Deﬁned concentrations of
enileukin diftitox were added to allogeneic MLCs at the beginning
f culture, as described in Methods. Shown are means ( standard
rrors) derived from 3 replicates per experimental condition. The
xperiment shown is representative of 2 experiments.
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Denileukin Diftitox as GVHD Prophylaxis 901roliferative responsiveness of third-party allogeneic
LCs when added at a 1:4 dilution (Figure 2).
yeloabative Autografts Followed by
ethotrexate Combined with Denileukin Diftitox
Autologous marrow transplantation with post-
rafting MTX and denileukin diftitox (9 g/kg/day 
days, n 2; 18 g/kg/day 6 days, n 1) was done
o determine denileukin diftitox toxicity after myeloa-
lative conditioning in the absence of allogeneic ef-
ects. The autograft recipient given MTX and de-
ileukin diftitox 18 g/kg/day died from diffuse
bdominal hemorrhage 13 days after transplantation.
ne of the 2 autograft recipients given denileukin
iftitox 9 g/kg/day was a long-term survivor; the
ther died of hemorrhagic enteritis on day 5 after
ransplantation.
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igure 2. Inhibition of proliferative responsiveness in canine allo-
eneic MLCs by the addition of sera from denileukin diftitox–
reated dogs. Sera obtained from dogs immediately before (Pre) and
0 minutes after (Post) IV injection of denileukin diftitox 9 g/kg
ere added to third-party allogeneic MLCs at the beginning of
ulture (1:4 volume/volume ratio), as described in Methods. Shown
re means ( standard errors) derived from 6 replicates per exper-
mental condition. The experiment shown is representative of 5
xperiments.
able 1. Dogs Administered 9.2-Gy TBI and Hematopoietic Grafts Fr
iftitox for Immunosuppression after Transplantation*
Dog
GVHD
Clinical Histological Onset (
345 Yes S, L, G 9
512 Yes S, L, G 13
571 No — —
508 Yes S, L, G 14
505 Yes S, L, G 14
848 Yes S, L, G 12
edian — — 13
HV, canine herpes virus infection; S, skin; L, liver; G, gut.
MTX 0.4 mg/kg/day IV on days 1, 3, 6, and 11 after transplantat
transplantation.
Euthanized because of poor clinical condition.LA-Nonidentical Hematopoitic Cell Grafts with
ostgrafting MTX and Denileukin Diftitox
Given the possibility of increased gut toxicity with
he higher denileukin diftitox dose, a dosage escalation
bove 9 g/kg/day was not attempted in allograft
ecipients. The 6 allograft recipients given a combi-
ation of MTX and denileukin diftitox in the current
tudy had a median survival of 16 days (range, 13-18
ays) (Table 1). All recipients engrafted with 98%
onor chimerism, and 1 dog died on posttransplanta-
ion day 13 with hepatitis and pancreatitis related to
anine herpes virus infection without clinical or his-
opathologic evidence of GVHD. Lymphocyte counts
eyond posttransplantation day 10 were slightly lower
or the study group compared with historical controls
iven MTX only (P  .02; Wilcoxon test) (Figure 3).
he main noticeable denileukin diftitox toxicity at a dose
f 9 g/kg/day consisted of generalized but transient
rticaria, which occurred in all denileukin diftitox–
reated dogs within minutes of injection. Five recipients
83%) developed rapidly progressive 3-system GVHD
nd had to be euthanized for poor clinical condition
etween posttransplantation days 14 and 18 (Table 1).
VHD of skin, liver, and gut was conﬁrmed by his-
opathology. The median survival in the MTX/de-
ileukin diftitox–treated recipients was similar to that
f historical controls given MTX alone (median sur-
ival, 20 days; range, 11-100 days) (Table 2) [18-20].
ISCUSSION
In vitro experiments that preceded the in vivo
ransplantation studies showed complete abrogation
f proliferative responsiveness in canine allogeneic
LCs in the presence of 1010 molar concentrations
f denileukin diftitoxin, indicating effective targeting
f alloactivated canine T cells expressing the high-
fﬁnity IL-2R. This ﬁnding is in keeping with the
roven cross-reactivity of recombinant human IL-2
-Nonidentical Unrelated Donors, Followed by MTX and Denileukin
Chimerism
(% Donor)
Survival
(Days) Cause of Death
>99 14 Euthanized†
100 18 Euthanized†
>99 13 CHV
>98 18 Euthanized†
>99 17 Euthanized†
>99 15 Euthanized†
— 16 —
ileukin diftitox 9 g/kg/day IV on days 2, 4, 5, 7, 8, and 10 afterom DLA
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M. Mielcarek et al.902ith canine T cells [22,23]. In addition, sera obtained
rom dogs 20 minutes after IV injection of 9 g/kg
enileukin diftitox completely inhibited the prolifera-
ive responsiveness of third-party allogeneic MLCs
hen added at a 1:4 dilution. Thus, our in vitro ﬁnd-
ngs demonstrated denileukin diftitox cross-reactivity
ith alloresponsive canine T cells and served as evi-
ence of the therapeutic serum levels in dogs.
Despite the reported denileukin diftitox half-life
f 1 hour in human patients [6], sustained responses
f steroid-refractory acute GVHD have been ob-
erved [11]. The denileukin diftitox dose and schedule
igure 3. Mean lymphocyte counts per L of dogs given 9.2 Gy of
ollowed by MTX/denileukin diftitox (solid line) or MTX alone (da
ere slightly lower for the study group than for historical controls (P
ere available for 26 of 35 recipients.
able 2. Dogs Administered 9.2-Gy TBI and Hematopoietic Grafts fro
TX Alone, MTX/CSP, or MTX/Denileukin Diftitox
Group Immunosuppression
No. of
Dogs
Studied
Graft
Failure M
1 None 72 6
2 MTX* 35 5
3 MTX  CSP† 16 1
4 MTX  denileukin diftitox‡ 6 0
MTX 0.4 mg/kg/d IV on days 1, 3, 6, and 11, and then once wee
108/kg; buffy coat, 17.0  8.0  108/kg.
MTX 0.4 mg/kg/d IV on days 1, 3, 6, and 11. In 10 dogs, CSP was
on days 8-26; 5 mg/kg twice daily by mouth on days 27-50, 2.5
mg/kg twice daily until day 100. In 6 dogs, CSP was given at 10
days 7-45.
MTX 0.4 mg/kg/day IV on days 1, 3, 6 and 11; denileukin diftito
bone marrow, 5.5  1.3  108/kg; buffy coat, 5.0  3.5  108/kg.sed in our study were chosen to allow administration
f the maximum tolerable dose before the typical
nset of GVHD (between posttransplantation days 9
nd 16 in this model). The administration of repetitive
oses of denileukin diftitox early after transplantation
as aimed at the early elimination of host-reactive
onor T cells arising in the recipient. Given the pos-
ibility of increased gut toxicity with the higher de-
ileukin diftitox dose (18 g/kg/day  6 doses) in
ecipients of autografts that served to determine de-
ileukin diftitox toxicity after myeloablative TBI in
he absence of allogeneic effects, a dosage escalation
nd hematopoietic grafts from DLA-nonidentical unrelated donors,
e) [18,19]. Lymphocyte counts beyond posttransplantation day 10
; Wilcoxon test). In the historical control group, lymphocyte counts
-Nonidentical Unrelated Donors, Followed by no Immunosuppression,
ival Days
Surviving
>100
Days
GVHD Onset
(Range in
Days) ReferencesRange
7-23 0 6-8 19, 20, and
concurrent
11->100 5 9-16 18,19
5->372 7 70-120 2 and concurrent
13-18 0 9-14 Current study
il day 102. Mean nucleated cell dose: bone marrow, 15.0  7.0 
at 7.5 mg/kg twice daily intramuscularly on days 0-7 and by mouth
twice daily by mouth on days 51-75, and then every other day 2.5
twice daily IV on days 0-6 and 15 mg/kg twice daily by mouth on
kg/day IV on days 2, 4, 5, 7, 8, and 10. Mean nucleated cell dose:TBI a
shed lin
 .02m DLA
Surv
edian
11
20
88
16
kly unt
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Denileukin Diftitox as GVHD Prophylaxis 903bove 9 g/kg/day was not attempted in allograft
ecipients.
The combination of marrow and PBMCs in this
nrelated DLA-nonidentical transplantation model
akes engraftment and subsequent development of
cute and fatal GVHD the rule [20], thus making this
stringent model for GVHD prevention. All 6 dogs
iven a combination of MTX and denileukin diftitox
n the current study engrafted. Although 1 of these
ogs died on posttransplantation day 13 with hepatitis
nd pancreatitis related to canine herpes virus infec-
ion without clinical or histopathologic evidence of
VHD, the other 5 recipients (83%) developed rap-
dly progressive 3-system GVHD mandating euthana-
ia. GVHD that was clearly distinguishable from regi-
en-related organ toxicity was subsequently conﬁrmed
y histopathologic criteria. The median survival of 16
ays (range, 13-18 days) in the group given MTX/
enileukin diftitox was similar to that in historical
ontrols given MTX alone (median survival, 20 days;
ange, 11-100 days) (Table 2) [18-20]. Thus, despite
chieving denileukin diftitox serum levels sufﬁcient to
ompletely suppress T-cell proliferative responsive-
ess in third-party allogeneic MLCs, the chosen reg-
men did not prevent, mitigate, or delay acute GVHD
n this preclinical large-animal model.
CSP was not combined with denileukin diftitox
ecause of previous data demonstrating a 60% re-
ection rate in recipients given DLA-nonidentical
rafts followed by CSP without MTX for GVHD
rophylaxis [24]. Apparently, CSP inhibits the en-
raftment-facilitating effect of donor T cells without
nhibiting rejection-mediating host natural killer cells.
he addition of MTX to CSP posttransplantation
esulted not only in uniform engraftment, but also in
substantial delay or prevention of GVHD in a large
roportion of dogs.
In our study, denileukin diftitox activity was de-
ermined in blood but not in lymph nodes or spleen of
anine allograft recipients. Thus, a possible explana-
ion for the failure of denileukin diftitox to prevent or
itigate GVHD might be unfavorable pharmacody-
amics, including impaired penetration of the drug
nto lymphatic tissues. Alternatively, denileukin difti-
ox treatment might result in the concomitant deple-
ion of CD4/CD25 regulatory T cells (Treg). Re-
ent clinical studies have shown an inverse correlation
etween Treg numbers and the likelihood of develop-
ng GVHD [25,26]. It has also been reported that
enileukin diftitox efﬁciently depleted alloreactive ca-
ine T cells and canine CD4/CD25 Treg from
LCs [23,27]. Furthermore, the presence of CSP
esulted in preferential depletion of Treg and “protec-
ion” of alloreactive T cells from denileukin diftitox
oxicity in these studies. The relative CSP resistance
f Treg would explain why, in contrast to MTX/de-ileukin diftitox, MTX/CSP was effective in attenu-
ting GVHD in this model.
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